Reipet – Lifestyle
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 12, 2026
Rigel Reports First Quarter 2026 Financial Results
May 5, 2026
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
April 28, 2026
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
March 31, 2026